Objective: This post hoc analysis evaluated the efficacy of lurasidone in patients with acute schizophrenia with prominent positive symptoms. Methods: Patient-level data were pooled from 5 similarly designed, multiregional, randomized, double-blind, placebocontrolled, 6-week studies of fixed-dose lurasidone (40, 80, 120, or 160 mg/d) in adult patients with acute schizophrenia. Patients with prominent positive symptoms were defined as those with baseline Positive and Negative Syndrome Scale (PANSS) positive subscale score > negative subscale score. Treatment response was defined as ≥30% decrease from baseline in PANSS total score at week 6 (last observation carried forward [LOCF] 6, 6, 8, and 3, respectively). In patients without prominent positive symptoms, treatment response at week 6 LOCF was observed in 35.7% of patients in the placebo group and 50.0%, 52.1%, 54.5%, and 60.4% of patients in the lurasidone 40, 80, 120, and 160 mg/d groups, respectively (NNT of 7, 7, 6, and 5, respectively Results: Total 510 Asian patients were enrolled and dosed in OL phase (total population: n=1429; China: n=296, Japan: n=175, Korea: n=19, Taiwan: n=20); 344 Asian patients were randomized in DB phase (total population: PP3M=504; PP1M=512; China: PP3M=104; PP1M=106; Japan: PP3M=52; PP1M=56; Korea: PP3M=7; PP1M=5; Taiwan: PP3M=7; PP1M=7). The Kaplan-Meier estimate of the difference (95% CI) between the treatment groups (PP3M-PP1M) in percentages of patients who remained relapse free (primary efficacy endpoint) was similar in the larger 2 subgroups (China: 1.1% [-6.1%; 8.3%]; Japan: 5.1% [-12.0%; 22.2%]) and the total population (1.2% [-2.7%; 5.1%]); the lower bounds of the 95% CI for all subgroups were larger than the pre-specified non-inferiority margin of -15%. Incidences of treatmentemergent adverse events (TEAEs) during the OL phase (China: 198/296 [66.9%] (PP3M vs. PP1M, China: 36.5% vs. 34.9%; Japan: 25.0% vs. 19.6%). Conclusions: PP3M was non-inferior to PP1M and was similarly tolerable in both total population, and Asian patients with schizophrenia.
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